Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Amylyx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Amylyx Pharmaceuticals's regulatory disclosures and financial reporting.
Amylyx Pharmaceuticals granted Chief Medical Officer Camille L. Bedrosian equity awards on March 5, 2026. She received stock options for 143,985 shares at an exercise price of $0.00 and 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to continued service. Twenty-five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also contingent on ongoing service.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an open-market sale of common stock tied to tax withholding. On March 2, he sold 29,282 shares at a weighted average price of $14.4717 per share to cover withholding obligations from vesting restricted stock units. The filing notes these sales were automatic and not at his discretion, and he continued to hold 3,334,616 shares of Amylyx common stock directly after the transaction.
Amylyx Pharmaceuticals director and Co-CEO Joshua B. Cohen reported an automatic tax-related share sale. On March 2, 2026, 29,282 shares of common stock were sold at a weighted average price of $14.484 per share to cover tax withholding owed on vesting restricted stock units.
The filing notes these sales were required to satisfy withholding obligations and were not made at Cohen’s discretion. After the transaction, he continues to directly own 3,334,683 shares of Amylyx common stock, indicating he retains a substantial equity stake in the company.
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian reported an automatic sale of 6,461 shares of common stock on March 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were sold at a weighted average price of $14.5806 per share in multiple trades between $14.440 and $14.945. After these tax-related sales, Bedrosian held 169,295 shares of Amylyx common stock directly.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported an automatic share sale related to tax withholding. On March 2, 2026, he sold 7,909 shares of common stock in an open-market transaction at a weighted average price of $14.5216 per share to cover taxes from restricted stock unit vesting.
After this sale, he directly held 165,638 shares. The filing also notes indirect holdings through several trusts, including 100,000 shares, 15,459 shares and 11,072 shares, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of 6,844 shares of common stock on March 2, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $14.5205 per share, and she held 134,430 shares afterward.
Amylyx Pharmaceuticals, Inc. filed an automatic shelf registration on March 3, 2026 to register an offering program for common stock, preferred stock, debt securities, warrants and units to be sold from time to time.
The prospectus states Amylyx is a well-known seasoned issuer using Form S-3ASR and may sell securities on a continuous or delayed basis; specific terms will be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol AMLX, with a closing sale price of $15.30 on March 2, 2026.
Amylyx Pharmaceuticals describes its 2025 business, drug pipeline and regulatory context in its annual report. The company had an aggregate market value of common equity held by non‑affiliates of $518.2 million as of June 30, 2025, with 110,536,944 shares outstanding as of February 23, 2026.
The lead asset, avexitide, targets post‑bariatric hypoglycemia affecting an estimated 160,000 people in the U.S. and is in the 75‑patient Phase 3 LUCIDITY trial, with topline data expected in Q3 2026. The report also highlights positive Phase 2 HELIOS data for AMX0035 in Wolfram syndrome, initiation and early safety data from the Phase 1 LUMINA trial of AMX0114 in ALS, selection of long‑acting GLP‑1 antagonist AMX0318 for PBH and other rare diseases, and a patent estate including 23 issued U.S. patents and 257 granted foreign patents as of December 31, 2025.
Amylyx Pharmaceuticals reported a smaller net loss for 2025 while pivoting firmly to late-stage development of avexitide for post-bariatric hypoglycemia (PBH). Net loss for 2025 was $144.7 million, or $1.53 per share, about half the $301.7 million, or $4.43 per share, loss in 2024. Product revenue fell from $87.4 million in 2024 to zero in 2025 as the company redirected resources.
Research and development expenses were $90.4 million in 2025, down from $104.1 million, while selling, general, and administrative expenses dropped sharply to $62.9 million from $114.3 million, reflecting reduced consulting and professional services. Cash, cash equivalents, and marketable securities were $317.0 million at December 31, 2025, up from $176.5 million a year earlier, supporting a stated cash runway into 2028.
Operationally, recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete, with last participants expected to be randomized and dosed in Q1 2026 and topline data anticipated in Q3 2026, targeting potential U.S. commercialization in 2027 if approved. The company is also advancing AMX0114 for amyotrophic lateral sclerosis in the Phase 1 LUMINA trial, with Cohort 2 enrollment expected to complete in March 2026, and progressing AMX0318 toward a planned investigational new drug filing in 2027.
Justin B. Klee filed a Form 144 proposing the sale of 57,529 common shares tied to the vesting of restricted stock units through Morgan Stanley Smith Barney LLC on 03/02/2026. The filing lists prior open‑market sales by Mr. Klee in January–February 2026, including sales of 136,193 shares on 01/15/2026 and 15,500 shares on 02/02/2026.